Abst0919 #ACR21 @RheumNow Phase III COAST-V 52W (PBO)-controlled study examined the efficacy of IXE in pts with active AS. SF-36 bodily pain, improvements were observed at W16 & W52 whether inflammation was controlled or not per MRI, CRP, MRI+CRP, or BASDAI 5/6. https://t.co/uHLwFctzPr

2 year extension study on Upadacitinib in active AS ⭐️ASAS40 response maintained ⭐️MRI SPARCC scores decreased and maintained ⭐️infections most common AE ⭐️NO MACE, lymphoma, skin cancer, GI perforations Abs#924 #ACR21 #ACRBest @RheumNow https://t.co/725IRAOgtW https://t.co/FVUoCi6aoQ

• Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondyli…

No significant difference in effectiveness/treatment survival of different TNFi in axSpA Failure of 1st TNFi did not diminish effectiveness of a second TNFi Abs#938 #ACR21 @RheumNow https://t.co/SLrOV7wmvU https://t.co/fkpmseVwF6

• Comparative Effectiveness and Treatment Survival of Different TNF Inhibitors fo…

Abst 0947 #ACR21 @RheumNow KikGR x TNFDARE/+ mice study assessed contribution of gut-derived T cells to increased joint inflammation through production of pro-inflammatory cytokines like IL-17 and TNF. Photolabeled gut-trafficked T cells are observed in the Achilles enthesis

No evidence to show increased risk of incident hypertension w/ TNFi use, after accounting for baseline & time-dependent confounding factors, in prospective AS cohort. Abs 0910 #ACR21 #RheumNow @RheumNow https://t.co/1SpQ51ftlK

• The Association of TNF Inhibitor Use with Incident Hypertension in Ankylosing S…

French, real-world axSpA cohort analysis shows SEC and TNFi retention rates similar. What do you see in your practice? Abs 0911 #ACR21 #RheumNow @RheumNow https://t.co/vu3zUwfktl https://t.co/v6DLjWJMn4

• Drug Retention of Tumor Necrosis Factors and IL-17 Inhibitors in Axial Spondylo…

@rheum_cat presenting a really well designed study looking at association between TNFi use and incident hypertension in axSpA. No association found. Abstr#0910 #ACR21 @RheumNow https://t.co/w7o1oDreVL

Abst0569 #acr21 @RheumNow mortality in SpA:⬆️ overall mortality in AS (RR 1.64, 95% CI: 1.49-1.80,) but not PsA (RR: 1.12, 95% CI: 0.96-1.30). CV, resp & infection specific mortality significantly higher for PsA Cancer related mortality in PsA not higher than the gen pop

Abst 0562 Ungprasert & colleagues examine hospitalization and resource utilization among patients with #AnkylosingSpondylitis - Prevalence is high - Infection was among the most common reasons for hospitalization (sepsis, pneumonia, UTI) #ACR21 @RheumNow https://t.co/UftoFllE1v

Abst0907 #ACR21 @RheumNow observation of GLAS cohort of nrAxSpA pts over 6 yrs showed ~10% of pts progress to AS every 2 years. Specifically after two, four and six years, 8/79 (10.1%), 4/48 (8.3%) and 3/24 (12.5%) nr-axSpA patients progressed to AS. https://t.co/hVpNz1kEgE

Prospective multicenter Screening for Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Study evaluated 240 patients with axSpA ⭐️Imaging of the SIJ and spine DOES NOT differ in Ps axSpA or axSpA associated with iritis or colitis Abst# 0902 #ACR21 #ACRBest @RheumNow https://t.co/Y2bRlysXI5

The rate of progression of nr-axSpA to AS is ~10% every 2 years. Study of 79 patients over 6 years, radiographic progression was 10.1% after 2 years (8/79), 8.3% between 2-4 years (4/48), and 12.5% between 4-6 years (3/24) @RheumNow #ACR21 Abst#0907 https://t.co/hOhpngANIl https://t.co/PiKDgiTES2

• Radiographic Sacroiliitis Progression up to Six Years of Follow-Up in Patients …